

VITAL THERAPIES INC  
Form 8-K  
March 07, 2017

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934  
Date of Report (Date of earliest event reported): March 7, 2017

VITAL THERAPIES, INC.  
(Exact name of registrant as specified in its charter)

Delaware                      001-36201                      56-2358443  
(State or other jurisdiction      (Commission File Number) (IRS Employer Identification No.)  
of incorporation)

15010 Avenue of Science, Suite 200      92128  
San Diego, CA  
(Address of principal executive offices) (Zip Code)  
Registrant's telephone number, including area code: (858) 673-6840

---

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 2.02. Results of Operations and Financial Condition.

On March 7, 2017, Vital Therapies, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2016. In its press release, the Company also provided a corporate update and reported that it would be holding a conference call on March 7, 2017 to discuss its financial results for the fourth quarter and fiscal year ended December 31, 2016. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this current report shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission, whether filed before or after the date hereof regardless of any general incorporation language in any such filing, unless the registrant expressly sets forth in such filing that such information is to be considered "filed" or incorporated by reference therein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
-------------	-------------

99.1	Press Release, dated March 7, 2017
------	------------------------------------

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VITAL THERAPIES, INC.

By: /s/ Michael V. Swanson  
Michael V. Swanson  
Chief Financial Officer  
Date: March 7, 2017

---

EXHIBIT INDEX

Exhibit No.	Description
-------------	-------------

99.1	Press Release, dated March 7, 2017
------	------------------------------------